Last 12 months
Inside the activity.
2 purchase rows · 116 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 15 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 29 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 31 |
| Apr 2026 | 0 | 9 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 11 |
| Jul 2026 | 2 | 6 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 26, 2026 23:09 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 21,072 | $0.00 Strike: $32.60 | $0.00 |
DisclosureSEC source: 0000874015-26-000212 · edgardoc.xml · derivative · entry 8 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,072 shares Expires 2032-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 23:09 UTC |
Monia Brett PDirector · Chief Executive Officer
|
SaleCommon Stock | 21,072 | $78.49 | $1,653,941.28 |
DisclosureSEC source: 0000874015-26-000212 · edgardoc.xml · nonDerivative · entry 4 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 245,571 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.005 to $78.78 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 23:09 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 21,072 | $32.60 | $686,947.20 |
DisclosureSEC source: 0000874015-26-000212 · edgardoc.xml · nonDerivative · entry 3 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 266,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 23:09 UTC |
Swayze EricEVP Research
|
SaleCommon Stock | 10,602 | $79.18 | $839,491.80 |
DisclosureSEC source: 0000874015-26-000211 · edgardoc.xml · nonDerivative · entry 1 Swayze Eric · CIK 0001791058 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,759 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 6, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.00 to $79.46 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 23:09 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 14,565 | $0.00 Strike: $32.60 | $0.00 |
DisclosureSEC source: 0000874015-26-000212 · edgardoc.xml · derivative · entry 7 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,072 Underlying: Common Stock · 14,565 shares Expires 2032-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 23:09 UTC |
Monia Brett PDirector · Chief Executive Officer
|
SaleCommon Stock | 14,565 | $78.41 | $1,142,082.43 |
DisclosureSEC source: 0000874015-26-000212 · edgardoc.xml · nonDerivative · entry 2 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 245,571 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.87 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 23:09 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 14,565 | $32.60 | $474,819.00 |
DisclosureSEC source: 0000874015-26-000212 · edgardoc.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 260,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 21:26 UTC |
BERTHELSEN SPENCER RDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $24.42 | $0.00 |
DisclosureSEC source: 0000874015-26-000207 · edgardoc.xml · derivative · entry 4 BERTHELSEN SPENCER R · CIK 0001181548 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2026-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 21:26 UTC |
BERTHELSEN SPENCER RDirector
|
SaleCommon Stock | 8,000 | $73.49 | $587,920.00 |
DisclosureSEC source: 0000874015-26-000207 · edgardoc.xml · nonDerivative · entry 2 BERTHELSEN SPENCER R · CIK 0001181548 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,013 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 21:26 UTC |
BERTHELSEN SPENCER RDirector
|
Exercise / conversionCommon Stock | 8,000 | $24.42 | $195,360.00 |
DisclosureSEC source: 0000874015-26-000207 · edgardoc.xml · nonDerivative · entry 1 BERTHELSEN SPENCER R · CIK 0001181548 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:26 UTC |
Kordasiewicz Holly B.EVP, Chief Development Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $60.89 | $0.00 |
DisclosureSEC source: 0000874015-26-000208 · edgardoc.xml · derivative · entry 10 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,000 shares Expires 2027-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:26 UTC |
Kordasiewicz Holly B.EVP, Chief Development Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,951 | $0.00 Strike: $60.89 | $0.00 |
DisclosureSEC source: 0000874015-26-000208 · edgardoc.xml · derivative · entry 9 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 7,951 shares Expires 2027-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:26 UTC |
Kordasiewicz Holly B.EVP, Chief Development Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 19,895 | $0.00 Strike: $56.78 | $0.00 |
DisclosureSEC source: 0000874015-26-000208 · edgardoc.xml · derivative · entry 8 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,895 shares Expires 2028-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:26 UTC |
Kordasiewicz Holly B.EVP, Chief Development Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $32.60 | $0.00 |
DisclosureSEC source: 0000874015-26-000208 · edgardoc.xml · derivative · entry 7 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2032-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:26 UTC |
Kordasiewicz Holly B.EVP, Chief Development Officer
|
SaleCommon Stock | 19,842 | $74.05 | $1,469,306.05 |
DisclosureSEC source: 0000874015-26-000208 · edgardoc.xml · nonDerivative · entry 6 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,458 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2026 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.735 to $74.28 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:26 UTC |
Kordasiewicz Holly B.EVP, Chief Development Officer
|
SaleCommon Stock | 41,004 | $73.09 | $2,997,121.77 |
DisclosureSEC source: 0000874015-26-000208 · edgardoc.xml · nonDerivative · entry 5 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,300 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2026 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.68 to $73.67 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:26 UTC |
Kordasiewicz Holly B.EVP, Chief Development Officer
|
Exercise / conversionCommon Stock | 19,895 | $56.78 | $1,129,638.10 |
DisclosureSEC source: 0000874015-26-000208 · edgardoc.xml · nonDerivative · entry 4 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:26 UTC |
Kordasiewicz Holly B.EVP, Chief Development Officer
|
Exercise / conversionCommon Stock | 12,000 | $32.60 | $391,200.00 |
DisclosureSEC source: 0000874015-26-000208 · edgardoc.xml · nonDerivative · entry 3 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:26 UTC |
Kordasiewicz Holly B.EVP, Chief Development Officer
|
Exercise / conversionCommon Stock | 21,000 | $60.89 | $1,278,690.00 |
DisclosureSEC source: 0000874015-26-000208 · edgardoc.xml · nonDerivative · entry 2 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:26 UTC |
Kordasiewicz Holly B.EVP, Chief Development Officer
|
Exercise / conversionCommon Stock | 7,951 | $60.89 | $484,136.39 |
DisclosureSEC source: 0000874015-26-000208 · edgardoc.xml · nonDerivative · entry 1 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:59 UTC |
Reikes Peter NDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,753 | $0.00 Strike: $75.13 | $0.00 |
DisclosureSEC source: 0000874015-26-000203 · edgardoc.xml · derivative · entry 1 Reikes Peter N · CIK 0001753652 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,753 Underlying: Common Stock · 10,753 shares Expires 2036-06-04 F1 · derivative.exercise_date: Grant of 06/04/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in three equal annual installments, the first installment vesting on 06/04/2027. The option shall be fully vested and exercisable on 06/04/2029. The stock option was exercisable as to 0 shares on 06/04/2026. F1 · derivative.expiration_date: Grant of 06/04/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in three equal annual installments, the first installment vesting on 06/04/2027. The option shall be fully vested and exercisable on 06/04/2029. The stock option was exercisable as to 0 shares on 06/04/2026. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:59 UTC |
HANTSON LUDWIGDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,753 | $0.00 Strike: $75.13 | $0.00 |
DisclosureSEC source: 0000874015-26-000202 · edgardoc.xml · derivative · entry 1 HANTSON LUDWIG · CIK 0001491435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,753 Underlying: Common Stock · 10,753 shares Expires 2036-06-04 F1 · derivative.exercise_date: Grant of 06/04/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in three equal annual installments, the first installment vesting on 06/04/2027. The option shall be fully vested and exercisable on 06/04/2029. The stock option was exercisable as to 0 shares on 06/04/2026. F1 · derivative.expiration_date: Grant of 06/04/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in three equal annual installments, the first installment vesting on 06/04/2027. The option shall be fully vested and exercisable on 06/04/2029. The stock option was exercisable as to 0 shares on 06/04/2026. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:34 UTC |
BERTHELSEN SPENCER RDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $24.42 | $0.00 |
DisclosureSEC source: 0000874015-26-000188 · edgardoc.xml · derivative · entry 4 BERTHELSEN SPENCER R · CIK 0001181548 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2026-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:34 UTC |
BERTHELSEN SPENCER RDirector
|
SaleCommon Stock | 8,000 | $75.67 | $605,360.00 |
DisclosureSEC source: 0000874015-26-000188 · edgardoc.xml · nonDerivative · entry 2 BERTHELSEN SPENCER R · CIK 0001181548 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,013 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:34 UTC |
BERTHELSEN SPENCER RDirector
|
Exercise / conversionCommon Stock | 8,000 | $24.42 | $195,360.00 |
DisclosureSEC source: 0000874015-26-000188 · edgardoc.xml · nonDerivative · entry 1 BERTHELSEN SPENCER R · CIK 0001181548 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2026 Filed May 15, 2026 22:15 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,220 | $0.00 Strike: $32.60 | $0.00 |
DisclosureSEC source: 0000874015-26-000185 · edgardoc.xml · derivative · entry 6 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,637 Underlying: Common Stock · 3,220 shares Expires 2032-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2026 Filed May 15, 2026 22:15 UTC |
Monia Brett PDirector · Chief Executive Officer
|
SaleCommon Stock | 3,220 | $78.68 | $253,347.35 |
DisclosureSEC source: 0000874015-26-000185 · edgardoc.xml · nonDerivative · entry 4 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 242,662 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.075 to $79.01 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| May 14, 2026 Filed May 15, 2026 22:15 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 3,220 | $32.60 | $104,972.00 |
DisclosureSEC source: 0000874015-26-000185 · edgardoc.xml · nonDerivative · entry 3 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 245,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2026 Filed May 15, 2026 22:15 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,316 | $0.00 Strike: $32.60 | $0.00 |
DisclosureSEC source: 0000874015-26-000185 · edgardoc.xml · derivative · entry 5 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,857 Underlying: Common Stock · 1,316 shares Expires 2032-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2026 Filed May 15, 2026 22:15 UTC |
Monia Brett PDirector · Chief Executive Officer
|
SaleCommon Stock | 1,316 | $78.01 | $102,665.11 |
DisclosureSEC source: 0000874015-26-000185 · edgardoc.xml · nonDerivative · entry 2 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 242,662 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.025 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| May 13, 2026 Filed May 15, 2026 22:15 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 1,316 | $32.60 | $42,901.60 |
DisclosureSEC source: 0000874015-26-000185 · edgardoc.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 243,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC |
LOSCALZO JOSEPHDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $64.80 | $0.00 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · derivative · entry 14 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2029-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC |
LOSCALZO JOSEPHDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $60.20 | $0.00 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · derivative · entry 13 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2030-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC |
LOSCALZO JOSEPHDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $42.88 | $0.00 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · derivative · entry 12 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2028-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC |
LOSCALZO JOSEPHDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,321 | $0.00 Strike: $41.08 | $0.00 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · derivative · entry 11 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,321 shares Expires 2033-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC |
LOSCALZO JOSEPHDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $40.05 | $0.00 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · derivative · entry 10 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2031-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC |
LOSCALZO JOSEPHDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,968 | $0.00 Strike: $38.06 | $0.00 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · derivative · entry 9 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,968 shares Expires 2032-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC |
LOSCALZO JOSEPHDirector
|
SaleCommon Stock | 17,781 | $75.58 | $1,343,934.21 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · nonDerivative · entry 8 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,330 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 18, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.495 to $75.98 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC |
LOSCALZO JOSEPHDirector
|
SaleCommon Stock | 59,508 | $74.90 | $4,457,292.02 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · nonDerivative · entry 7 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,111 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 18, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.49 to $75.49 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC |
LOSCALZO JOSEPHDirector
|
Exercise / conversionCommon Stock | 16,000 | $64.80 | $1,036,800.00 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · nonDerivative · entry 6 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC |
LOSCALZO JOSEPHDirector
|
Exercise / conversionCommon Stock | 12,000 | $60.20 | $722,400.00 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · nonDerivative · entry 5 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC |
LOSCALZO JOSEPHDirector
|
Exercise / conversionCommon Stock | 16,000 | $42.88 | $686,080.00 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · nonDerivative · entry 4 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC |
LOSCALZO JOSEPHDirector
|
Exercise / conversionCommon Stock | 10,321 | $41.08 | $423,986.68 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · nonDerivative · entry 3 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC |
LOSCALZO JOSEPHDirector
|
Exercise / conversionCommon Stock | 12,000 | $40.05 | $480,600.00 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · nonDerivative · entry 2 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC |
LOSCALZO JOSEPHDirector
|
Exercise / conversionCommon Stock | 10,968 | $38.06 | $417,442.08 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · nonDerivative · entry 1 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:30 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,111 | $0.00 Strike: $47.11 | $0.00 |
DisclosureSEC source: 0000874015-26-000182 · edgardoc.xml · derivative · entry 5 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,111 shares Expires 2034-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:30 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 1,431 | $74.45 | $106,534.23 |
DisclosureSEC source: 0000874015-26-000182 · edgardoc.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,014 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.07 to $74.92 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:30 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 8,680 | $73.35 | $636,704.04 |
DisclosureSEC source: 0000874015-26-000182 · edgardoc.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,445 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.95 to $73.64 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:30 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 10,111 | $47.11 | $476,329.21 |
DisclosureSEC source: 0000874015-26-000182 · edgardoc.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2026 Filed Apr 30, 2026 20:21 UTC |
Baroldi JosephEVP, Chief Business Officer
|
SaleCommon Stock | 1,626 | $71.79 | $116,726.80 |
DisclosureSEC source: 0000874015-26-000179 · edgardoc.xml · nonDerivative · entry 1 Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,909 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.67 to $71.825 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.